Immunotherapy plus testosterone for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study combines an immunotherapy drug called sipuleucel-T (which boosts your immune system to fight cancer) with a high-dose testosterone treatment called bipolar androgen therapy. The goal is to see if this combination can help men with advanced prostate cancer that is not responding to usual hormone therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have prostate cancer that has spread to other parts of your body and is no longer controlled by hormone therapy (castration-resistant).
- You should have no or only mild symptoms from your cancer, but your doctor will confirm this.
- You must not have had chemotherapy for castration-resistant prostate cancer before.
- You must not have had sipuleucel-T (Provenge) or high-dose testosterone treatment in the past.
- You must not have an active autoimmune disease or an active HIV, Hepatitis B, or Hepatitis C infection.
- You need to be generally well enough to participate, with a performance status of 0 or 1.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study combines two treatments: pembrolizumab, which helps your immune system fight cancer, and a targeted radioactive medicine (177Lu-PSMA-617) that seeks out and damages prostate cancer cells. It may help men whose prostate cancer has spread despite initial hormone therapy.
This trial tests whether a short course of high-dose testosterone followed by a radioactive drug (PSMA-617) can help men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to make cancer cells more sensitive to the radiation.
This study tests a combination of two drugs for men with advanced prostate cancer that has stopped responding to hormone therapy. The drugs are cabozantinib (a pill that may slow cancer growth) and a radioactive therapy that targets prostate cancer cells (177Lu-PSMA-617). The goal is to see if this combination is safe and effective.
This trial tests a new type of immune cell therapy (gamma delta T cells) targeted at a marker on prostate cancer cells to see if it can shrink bone metastases in advanced, castration-resistant prostate cancer. It’s for men who have already tried chemotherapy and newer hormone therapies and whose cancer is getting worse.
This trial combines two immune-boosting treatments, Sipuleucel-T and N-803, to see if they can better fight prostate cancer that has spread and stopped responding to hormone therapy. It aims to help your immune system attack the cancer more effectively.
This trial tests a combination of two treatments for advanced prostate cancer that has stopped responding to hormone therapy. One treatment is a targeted radiation therapy (177Lu-PSMA-617) and the other is an immunotherapy (sipuleucel-T) that helps your immune system fight the cancer.
Hear when a new Metastatic Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.